Literature DB >> 7875754

Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991.

V L Burt1, P Whelton, E J Roccella, C Brown, J A Cutler, M Higgins, M J Horan, D Labarthe.   

Abstract

The purpose of this study was to estimate the current prevalence and distribution of hypertension and to determine the status of hypertension awareness, treatment, and control in the US adult population. The study used a cross-sectional survey of the civilian, noninstitutionalized population of the United States, including an in-home interview and a clinic examination, each of which included measurement of blood pressure. Data for 9901 participants 18 years of age and older from phase 1 of the third National Health and Nutrition Examination Survey, collected from 1988 through 1991, were used. Twenty-four percent of the US adult population representing 43,186,000 persons had hypertension. The age-adjusted prevalence in the non-Hispanic black, non-Hispanic white, and Mexican American populations was 32.4%, 23.3%, and 22.6%, respectively. Overall, two thirds of the population with hypertension were aware of their diagnosis (69%), and a majority were taking prescribed medication (53%). Only one third of Mexican Americans with hypertension were being treated (35%), and only 14% achieved control in contrast to 25% and 24% of the non-Hispanic black and non-Hispanic white populations with hypertension, respectively. Almost 13 million adults classified as being normotensive reported being told on one or more occasions that they had hypertension; 51% of this group reported current adherence to lifestyle changes to control their hypertension. Hypertension continues to be a common finding in the general population. Awareness, treatment, and control of hypertension have improved substantially since the 1976-1980 National Health and Nutrition Examination Survey but continue to be suboptimal, especially in Mexican Americans.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7875754     DOI: 10.1161/01.hyp.25.3.305

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  619 in total

Review 1.  The role of diet in the prevention and treatment of hypertension.

Authors:  L J Appel
Journal:  Curr Atheroscler Rep       Date:  2000-11       Impact factor: 5.113

Review 2.  Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence?

Authors:  K A Payne; S Esmonde-White
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

Review 3.  Recent advances in the management of hypertension in the elderly.

Authors:  F J Gennari; A S Gennari
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

Review 4.  Use of gene markers to guide antihypertensive therapy.

Authors:  S T Turner; G L Schwartz; A B Chapman; E Boerwinkle
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 5.  Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension.

Authors:  M Ruzicka; F H Leenen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Quality of life with nonpharmacologic treatment of hypertension.

Authors:  J P Roel; C L Hildebrant; R H Grimm
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 7.  Systolic hypertension and cardiovascular risk reduction: a clinical review.

Authors:  W C Cushman
Journal:  Curr Hypertens Rep       Date:  2001-09       Impact factor: 5.369

Review 8.  Pharmacoeconomics of hypertension management: the place of combination therapy.

Authors:  E Ambrosioni
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 9.  Compliance, quality of life, and cost effectiveness.

Authors:  W B Stason
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

Review 10.  Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?

Authors:  S S Franklin
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.